Cargando…

Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus

BACKGROUND: Aspergillus flavus is one of the most common agents of invasive aspergillosis and is associated with high mortality. The orotomides are a new class of antifungal agents with a novel mechanism of action. An understanding of the pharmacodynamics (PD) of the lead compound F901318 is require...

Descripción completa

Detalles Bibliográficos
Autores principales:	Negri, Clara E, Johnson, Adam, McEntee, Laura, Box, Helen, Whalley, Sarah, Schwartz, Julie A, Ramos-Martín, V, Livermore, Joanne, Kolamunnage-Dona, Ruwanthi, Colombo, Arnaldo L, Hope, William W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909626/ https://www.ncbi.nlm.nih.gov/pubmed/28968675 http://dx.doi.org/10.1093/infdis/jix479

Ejemplares similares

Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease
por: Hope, William W., et al.
Publicado: (2017)

Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management
por: Rudramurthy, Shivaprakash M., et al.
Publicado: (2019)

The Dynamic Influence of Olorofim (F901318) on the Cell Morphology and Organization of Living Cells of Aspergillus fumigatus
por: du Pré, Saskia, et al.
Publicado: (2020)

Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response
por: Kovanda, Laura L., et al.
Publicado: (2017)

Potency of Olorofim (F901318) Compared to Contemporary Antifungal Agents against Clinical Aspergillus fumigatus Isolates and Review of Azole Resistance Phenotype and Genotype Epidemiology in China
por: Su, Huilin, et al.
Publicado: (2021)

In vitro antifungal susceptibility of clinical and environmental isolates of Aspergillus fumigatus and Aspergillus flavus in Brazil
por: Bedin Denardi, Laura, et al.
Publicado: (2017)

Aspergillus fumigatus and Aspergillus flavus-Specific IgG Cut-Offs for the Diagnosis of Chronic Pulmonary Aspergillosis in Pakistan
por: Jabeen, Kauser, et al.
Publicado: (2020)

Hydrophobic Effect of Amphiphilic Derivatives of Chitosan on the Antifungal Activity against Aspergillus flavus and Aspergillus parasiticus
por: Viegas de Souza, Ricchard Hallan Felix, et al.
Publicado: (2013)

Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei
por: Le, Thuy, et al.
Publicado: (2019)

Assessment of Antifungal Pharmacodynamics
por: Howard, Alex, et al.
Publicado: (2023)

Non-Aspergillus Hyaline Molds: A Host-Based Perspective of Emerging Pathogenic Fungi Causing Sinopulmonary Diseases
por: Jacobs, Samantha E., et al.
Publicado: (2023)

Diffuse panbronchiolitis, a potentially misdiagnosed sinopulmonary syndrome
por: Atici, Atilla G., et al.
Publicado: (2005)

Investigations on the Antifungal Effect of Nerol against Aspergillus flavus Causing Food Spoilage
por: Tian, Jun, et al.
Publicado: (2013)

N-Myristoyltransferase, a Potential Antifungal Candidate Drug-Target for Aspergillus flavus
por: Wang, Yu, et al.
Publicado: (2022)

RNA interference of Aspergillus flavus in response to Aspergillus flavus partitivirus 1 infection
por: Jiang, Yinhui, et al.
Publicado: (2023)

Drug-Resistant Aspergillus flavus Is Highly Prevalent in the Environment of Vietnam: A New Challenge for the Management of Aspergillosis?
por: Duong, Tra My N., et al.
Publicado: (2020)

In Vitro Antifungal Activity of Peltophorum dubium (Spreng.) Taub. extracts against Aspergillus flavus
por: Di Ciaccio, Lucía S., et al.
Publicado: (2020)

Antifungal Activity of Essential Oil and Plant-Derived Natural Compounds against Aspergillus flavus
por: Tian, Fei, et al.
Publicado: (2022)

Antifungal Effect of Autochthonous Aromatic Plant Extracts on Two Mycotoxigenic Strains of Aspergillus flavus
por: Boy, Francisco Ramiro, et al.
Publicado: (2023)

Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis
por: Stott, Katharine E., et al.
Publicado: (2018)

Aspergillus lentulus: An Under-recognized Cause of Antifungal Drug-Resistant Aspergillosis
por: Nematollahi, Saman, et al.
Publicado: (2021)

Evaluating statistical characteristics of biomarker-guided trial designs
por: Antoniou, Miranta, et al.
Publicado: (2015)

Sample size formula for joint modelling of longitudinal and time-to-event data in clinical trials
por: Powney, Matthew, et al.
Publicado: (2013)

Adjusting for informative missing outcome data in clinical trials with longitudinal study designs
por: Kolamunnage-Dona, Ruwanthi, et al.
Publicado: (2013)

Antifungal Activity of Essential Oil Compounds (Geraniol and Citral) and Inhibitory Mechanisms on Grain Pathogens (Aspergillus flavus and Aspergillus ochraceus)
por: Tang, Xi, et al.
Publicado: (2018)

Regulation of Conidiogenesis in Aspergillus flavus
por: Cho, He-Jin, et al.
Publicado: (2022)

The Mechanism of Antifungal Action of Essential Oil from Dill (Anethum graveolens L.) on Aspergillus flavus
por: Tian, Jun, et al.
Publicado: (2012)

Isolation of Antifungal Lactic Acid Bacteria (LAB) from “Kunu” against Toxigenic Aspergillus flavus
por: Olonisakin, Oluwafunmilayo Oluwakemi, et al.
Publicado: (2017)

Green extraction of polyphenols from citrus peel by-products and their antifungal activity against Aspergillus flavus
por: Liu, Yue, et al.
Publicado: (2021)

Screening of Bacillus velezensis E2 and the Inhibitory Effect of Its Antifungal Substances on Aspergillus flavus
por: Li, Shengjie, et al.
Publicado: (2022)

Mycobacterium chelonae-abscessus Complex Associated with Sinopulmonary Disease, Northeastern USA
por: Simmon, Keith E., et al.
Publicado: (2011)

Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis
por: Lestner, Jodi, et al.
Publicado: (2017)

Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
por: Antoniou, Miranta, et al.
Publicado: (2016)

Modelling variable dropout in randomised controlled trials with longitudinal outcomes: application to the MAGNETIC study
por: Kolamunnage-Dona, Ruwanthi, et al.
Publicado: (2016)

Joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis
por: Sudell, Maria, et al.
Publicado: (2016)

Correction to: joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis
por: Sudell, Maria, et al.
Publicado: (2018)

Correction: Antoniou, M.; et al. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J. Pers. Med. 2017, 7, 1
por: Antoniou, Miranta, et al.
Publicado: (2018)

Correction: Antoniou, M.; et al. Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size. J. Pers. Med. 2017, 7, 19
por: Antoniou, Miranta, et al.
Publicado: (2018)

Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size
por: Antoniou, Miranta, et al.
Publicado: (2017)

Time-dependent ROC curve analysis in medical research: current methods and applications
por: Kamarudin, Adina Najwa, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vve5gcf87kr6vbgsfspnjk759l